| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/24/2004 | EP1399158A1 Aromatase inhibitors as novel veterinary drugs |
| 03/24/2004 | EP1399157A1 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 03/24/2004 | EP1399156A2 Alkylidene pirazolidinedione derivatives and their use for treating diabetes and obesity |
| 03/24/2004 | EP1399155A2 Small molecules useful in the treatment of inflammatory disease |
| 03/24/2004 | EP1399154A1 3-fluoro-pyrrolidines as antidiabetic agents |
| 03/24/2004 | EP1399153A2 Pharmaceutical composition comprising a drug and a fatty acid or salt thereof |
| 03/24/2004 | EP1399152A1 Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester |
| 03/24/2004 | EP1399151A2 A method for treating inflammatory diseases by administering a ppar-delta agonist |
| 03/24/2004 | EP1399150A1 Vitamin c compositions |
| 03/24/2004 | EP1399149A2 Taxane prodrugs |
| 03/24/2004 | EP1399147A2 Therapeutic delivery of carbon monoxide |
| 03/24/2004 | EP1399146A1 Novel compounds and compositions as cathepsin inhibitors |
| 03/24/2004 | EP1399145A2 Pressure sensitive adhesive matrix patch for the treatment of onychomycosis |
| 03/24/2004 | EP1399144A1 Carbamate compounds for use in preventing or treating anxiety disorders |
| 03/24/2004 | EP1399143A1 Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia |
| 03/24/2004 | EP1399142A1 Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |
| 03/24/2004 | EP1399141A1 Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain |
| 03/24/2004 | EP1399140A1 Biological response modifier composition and uses thereof |
| 03/24/2004 | EP1399139A2 Compositions based on branched chain amino acids for improving the myocardial ventricular function in patients suffering from diabetes |
| 03/24/2004 | EP1399138A1 Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| 03/24/2004 | EP1399137A1 Sulfonamides |
| 03/24/2004 | EP1399136A2 Process for the preparation of dispersions |
| 03/24/2004 | EP1399134A2 Differential delivery of nitric oxide |
| 03/24/2004 | EP1399129A1 Compositions with controlled release of lactic acid at vaginal level |
| 03/24/2004 | EP1399127A1 Olopatadine formulations for topical administration |
| 03/24/2004 | EP1399120A1 Breath protection microcapsules |
| 03/24/2004 | EP1399119A2 Oral compositions and use thereof |
| 03/24/2004 | EP1399108A2 Preparation of a therapeutic composition |
| 03/24/2004 | EP1399105A2 Method for cleaning hard gelatine capsules |
| 03/24/2004 | EP1399021A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
| 03/24/2004 | EP1349558A4 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 03/24/2004 | EP1338281A4 Method for producing an immunotropic antiviral preparation |
| 03/24/2004 | EP1315508B1 Purine ribosides as antiarrhythmics |
| 03/24/2004 | EP1303517B1 Indoloquinazolinones |
| 03/24/2004 | EP1301176B1 Method for coating solid particles with a thermofusible agent, and resulting coated solid particles |
| 03/24/2004 | EP1299384B1 Indole derivatives useful for the treatment of cns disorders |
| 03/24/2004 | EP1296700A4 Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root |
| 03/24/2004 | EP1280796B1 Pyrimidinyl methyl indole derivatives with antibacterial activity |
| 03/24/2004 | EP1252164B1 Method for producing 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizine-5-yl acetic acid |
| 03/24/2004 | EP1242087B1 Analgesic compositions containing buprenorphine |
| 03/24/2004 | EP1214296B1 Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| 03/24/2004 | EP1212119B1 USE OF CYAMEMAZINE FOR the treatment of abrupt benzodiazepine withdrawal |
| 03/24/2004 | EP1200399B1 Vitamin d3 analogs |
| 03/24/2004 | EP1196416B1 Substituted purine derivatives as inhibitors of cell adhesion |
| 03/24/2004 | EP1190720B1 Liquid pharmaceutical composition for oral administration of bitter hydrolysis-susceptible active substances |
| 03/24/2004 | EP1173437B1 Thiazolidinedione derivative and its use as antidiabetic |
| 03/24/2004 | EP1161232B1 Hydroxy diphenyl urea sulfonamides as il-8 receptor antagonists |
| 03/24/2004 | EP1143964B1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
| 03/24/2004 | EP1140895B1 Thiopyran compounds as inhibitors of mmp |
| 03/24/2004 | EP1124809B1 Benzoylpyridazines |
| 03/24/2004 | EP1121456A4 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 03/24/2004 | EP1117641B1 Indolin derivatives as sun protection agents |
| 03/24/2004 | EP1113726B1 Use of neohesperidin dihydrochalcone for the manufacture of a medicament for preventing or treating elevated blood lipid level-related diseases |
| 03/24/2004 | EP1097150B1 Imidazolyl derivatives |
| 03/24/2004 | EP1094820B1 Use of bisphosphonates in the treatment of vascular restenosis |
| 03/24/2004 | EP1082110B1 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 03/24/2004 | EP1047690B1 Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission |
| 03/24/2004 | EP1045695B1 Use of 9-deoxy-2', 9-alpha-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f 1? to treat peripheral vascular disease |
| 03/24/2004 | EP1033981B1 Formulations and methods for reducing toxicity of antineoplastic agents |
| 03/24/2004 | EP1014990A4 Method of treating a tumor |
| 03/24/2004 | EP1003505B1 Heterocyclic vinylethers against neurological disorders |
| 03/24/2004 | EP0998930B1 Azasteroid compound for treating alopecia, hirsutism and seborrhea |
| 03/24/2004 | EP0986393B1 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer |
| 03/24/2004 | EP0922036B1 Arylalkanoyl pyridazines |
| 03/24/2004 | EP0912543B1 Crystalline (-)-3r,4r-trans-7-methoxy-2,2-dimethyl-3-phenyl-4-[4- 2-(pyrrolidin-1-yl)ethoxy]phenyl chromane, hydrogen fumarate |
| 03/24/2004 | EP0904079B1 Antidiabetic agents |
| 03/24/2004 | EP0873332B1 Discodermolide compounds and pharmaceutical compositions containing them for cancer therapy |
| 03/24/2004 | EP0869773B1 Archaeosomes, archaeosomes containing coenzyme q 10, and other types of liposomes containing coenzyme q 10 as adjuvants and as delivery vehicles |
| 03/24/2004 | EP0850319B1 Method for modulating cell apoptosis |
| 03/24/2004 | EP0819432B1 Antitumor agents comprising as the principal agent compounds containing silicon and nitrogen |
| 03/24/2004 | EP0795015B1 Plasmids suitable for il-2 expression |
| 03/24/2004 | EP0784469B1 Compositions for the delivery of antigens |
| 03/24/2004 | EP0781134B1 Scopolamine plaster |
| 03/24/2004 | EP0777670B1 Substituted camptothecin derivatives and process for their preparation |
| 03/24/2004 | CN2607134Y Citrene soft capsule medicine for curing biliary tract disease |
| 03/24/2004 | CN1484706A Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 03/24/2004 | CN1484646A Mikanolide derivatives their preparation and therapeutic uses |
| 03/24/2004 | CN1484644A Novel 7-azaindoles use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 03/24/2004 | CN1484642A Excitatory amino acid receptor antagonists |
| 03/24/2004 | CN1484640A Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists |
| 03/24/2004 | CN1484639A Geldanamycin derivative and method of treating cancer same |
| 03/24/2004 | CN1484638A I-aryl-or-I-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-b ligands |
| 03/24/2004 | CN1484633A N (phenylsulphonyl) glycine derivatives and their therapentic use |
| 03/24/2004 | CN1484537A Pharmacentical preparation for douches and/or irrigations of natural or puthological cavities in human body |
| 03/24/2004 | CN1484529A Gusuibu extracts for trvating osteoporosis and method for extracting same |
| 03/24/2004 | CN1484528A Pharmaceutical composition comprising wikstromol and/or mataires inal, its use as hepatoprotectant and process for their isolation from cedurs deodara |
| 03/24/2004 | CN1484527A Medicines for treatment and prevention of neurogenic pain |
| 03/24/2004 | CN1484526A Perturbed membrane-binding compounds |
| 03/24/2004 | CN1484525A Combinations of drugs (E. G chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 03/24/2004 | CN1484524A 5-HT IA veceptor subtype agonist |
| 03/24/2004 | CN1484523A Pharmaceutical composition containing citalopram |
| 03/24/2004 | CN1484522A Skin care product containing retinoids and phytoestrogens in a dual compartment package |
| 03/24/2004 | CN1484521A Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
| 03/24/2004 | CN1484493A 液体抗微生物组合物 Liquid antimicrobial composition |
| 03/24/2004 | CN1483820A Carcinoma of esophagus related gene-2 and use of coding protein thereof |
| 03/24/2004 | CN1483801A Health care wine containing dihydro-myricetin and myricetin composition |
| 03/24/2004 | CN1483729A Method for preparing 5-phenoxymethoy 1-2-ephedroxane |
| 03/24/2004 | CN1483716A Stibene derivative organic amine salt, its preparation method, use and medicinal composition |
| 03/24/2004 | CN1483478A Eye preparation formula adapted for therapentic medicine |
| 03/24/2004 | CN1483413A Medicinal composition for treationg virus infention of rlavivirus family, set group and packaged products |